



PRESS RELEASE

CUTISS opens subsidiary in France and secures first government grant to extend its Research and Development in regenerative medicine

- **The subsidiary CUTISS Innovation, based at Sophia Antipolis, Europe’s leading technology park, will focus on R&D and innovation in regenerative medicine.**
- **A grant of EUR 300,000 from the Region Provence-Alpes-Cote d’Azur will contribute towards the installation of a CUTISS laboratory at the site near Nice.**

France and Switzerland, 25 January 2022 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the opening of CUTISS Innovation, a wholly-owned subsidiary based at Europe’s largest leading technology park Sophia Antipolis, in the French department of Alpes Maritime. The company has also secured its first grant of EUR 300,000 from the Provence-Alpes-Côte d’Azur region that will be used to set up and launch the research laboratory.

CUTISS Innovation will support and extend the company’s R&D activities, focusing on the development of innovative break-throughs and products in the field of skin pigmentation restoration, and the automation of personalized regenerative medicine. As part of this, the company will work in close collaboration with dermatology stakeholders, clinics, and specialists, notably with Professor Thierry Passeron, Head of the Dermatology Unit at the Nice University Hospital and Team Leader of the Molecular Medicine Mediterranean Center.

Vincent Ronfard, Chief Innovation Officer at CUTISS AG and Director of CUTISS Innovation, commented: *“We are excited to establish our presence in this hotspot for innovation and dermatology which will enable our research team to push the boundaries in regenerative medicine. We are extremely grateful for the support we have received so far, particularly from the regional government who awarded the grant, and from Team Côte d’Azur and Sophia Antipolis Technopole.”*

The CUTISS Innovation laboratory is planned to be operational during Q2 2022, following the transfer of technology and recruitment of key professionals.

As part of the company’s implantation in the region, CUTISS was accompanied by Team Côte d’Azur, which helped the company establish contacts with stakeholders, including leading dermatology specialists from both the university hospital and the private sector.

About CUTISS AG

CUTISS is a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering. It is developing the first personalized and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries.

The lead product denovoSkin promises to take skin surgery to the next level and revolutionize current treatments. It is a bio-engineered and personalized dermo-epidermal human skin graft, currently in Phase IIb clinical trials in Switzerland and the European Union, with Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA.

CUTISS is also developing the world’s first machine that can automate the entire production process of the personalized skin graft. The company’s knowledge in skin bio-engineering and biology offers several growth opportunities in regenerative medicine.

Established in 2017, the company is a spin-off from University of Zurich (UZH) / University Children’s Hospital and a member of the accelerator Wyss Zurich. Headquartered at the Bio-Technopark in Zurich, it won the Top 100 Swiss Startup Award 2020, and has raised about CHF 50 million from private investors, family offices and public bodies.

Media contacts

CUTISS:

Cabinet Privé de Conseils (Switzerland)

Toomas Kull kull@cpc-pr.com | +41 767 480 174

Nick Miles miles@cpc-pr.com | +41 796 787 626